RESPONSE TO 2ND LINE CHEMOTHERAPY IN OVARIAN-CANCER OF EPITHELIAL ORIGIN

被引：4

作者：

MENCZER, J

BAITNER, S

MODAN, M

CHAITCHIK, S

BRENNER, H

机构：

[1] TEL AVIV UNIV,CHAIM SHEBA MED CTR,SACKLER SCH MED,DEPT CLIN EPIDEMIOL,TEL HASHOMER,ISRAEL

[2] TEL AVIV UNIV,CHAIM SHEBA MED CTR,SACKLER SCH MED,DEPT ONCOL,TEL HASHOMER,ISRAEL

来源：

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1981年 / 17卷 / 12期

关键词：

D O I：

10.1016/0014-2964(81)90005-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1259 / 1262

页数：4

共 15 条

[11] CANCER OF OVARY IN ISRAEL (1966-1971) [J].

SCHENKER, JG ;

MAZZOR, M .

GYNECOLOGIC ONCOLOGY, 1978, 6 (05) :397-410

[12]

SMITH JP, 1970, AM J OBSTET GYNECOL, V107, P691

[13] 2ND TRIAL DRUGS IN OVARIAN CANCER [J].

STANHOPE, CR ;

SMITH, JP ;

RUTLEDGE, F .

GYNECOLOGIC ONCOLOGY, 1977, 5 (01) :52-58

[14]

TWIGGS LB, 1977, CANCER TREAT REP, V61, P1369

[15] ADVANCED OVARIAN ADENOCARCINOMA - PROSPECTIVE CLINICAL-TRIAL OF MELPHALAN (L-PAM) VERSUS COMBINATION CHEMOTHERAPY [J].

YOUNG, RC ;

CHABNER, BA ;

HUBBARD, SP ;

FISHER, RI ;

BENDER, RA ;

ANDERSON, T ;

SIMON, RM ;

CANELLOS, GP ;

DEVITA, VT .

NEW ENGLAND JOURNAL OF MEDICINE, 1978, 299 (23) :1261-1266

← 1 2 →